Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

Status:
Unknown status

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.

Phase 1

Avidia